Polyguanosine motif increases cellular oligonucleotide uptake in the brain cortex

NeuroReport

Volumn 17, Issue 15, 2006, Pages 1579-1583

  Zhang, Zhiren ^a   Fauser, Uwe ^a   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Brain; CpG oligonucleotides; Polyguanosine motif

Indexed keywords

BIOTIN; CPG OLIGODEOXYNUCLEOTIDE; FLUORESCEIN ISOTHIOCYANATE; GUANOSINE DERIVATIVE; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA FLANKING REGION; FEMALE; INJECTION SITE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

AMINO ACID MOTIFS; ANIMALS; BIOTIN; CELL COUNT; CEREBRAL CORTEX; FEMALE; IMMUNOHISTOCHEMISTRY; INDOLES; MICROINJECTIONS; OLIGODEOXYRIBONUCLEOTIDES; RATS; RATS, INBRED LEW;

EID: 33749028157     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000234758.26610.0c     Document Type: Article

References (22)

1. Sapolsky RM. Neuroprotective gene therapy against acute neurological insults. Nat Rev Neurosci 2003; 4:61-69.
2. Forte A, Cipollaro M, Cascino A, Galderisi U. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr Drug Targets 2005; 6:21-29.
3. Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 2002; 13:579-604.
4. Neuwelt EA, Abbott NJ, Drewes L, Smith QR, Couraud PO, Chiocca EA, et al. Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery 1999; 44:604-608.
5. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-549.
6. Zhang Z, Weinschenk T, Schluesener HJ. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells. J Neuroimmunol 2005; 160:32-40.
7. Pisetsky DS. Immunostimulatory DNA: a clear and present danger? Nat Med 1997; 3:829-831.
8. Agrawal S. Antisense oligonucleotides: a possible approach for the chemotherapy of AIDS. In: Wickstrom E, editor. Prospects for antisense nucleic acid therapy of cancer and AIDS. New York: Wiley-Liss; 1991, pp. 143-158.
9. Wojcik WJ, Swoveland P, Zhang X, Vanguri P. Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat. J Pharmacol Exp Ther 1996; 278:404-410.
10. Prasad V, Hashim S, Mukhopadhyay A, Basu SK, Roy RP. Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. Antimicrob Agents Chemother 1999; 43:2689-2696.
11. Zhang Z, Guo K, Schluesener HJ. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif. J Neuroimmunol 2005; 161:68-77.
12. Lee SW, Song MK, Baek KH, Park Y, Kim JK, Lee CH, et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol 2000; 165:3631-3639.
13. Dalpke AH, Zimmermann S, Albrecht I, Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002; 106:102-112.
14. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7:3540-3543.
15. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59:5429-5432.
16. Ogawa S, Brown HE, Okano HJ, Pfaff DW. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept 1995; 59:143-149.
17. Chiasson BJ, Hooper ML, Murphy PR, Robertson HA. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur J Pharmacol 1992; 227:451-453.
18. Juliano RL, Yoo H. Aspects of the transport and delivery of antisense oligonucleotides. Curr Opin Mol Ther 2000; 2:297-303.
19. Biessen EA, Vietsch H, Kuiper J, Bijsterbosch MK, Berkel TJ. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 1998; 53:262-269.
20. Kaur H, Jaso-Friedmann L, Evans DL. Identification of a scavenger receptor homologue on nonspecific cytotoxic cells and evidence for binding to oligodeoxyguanosine. Fish Shellfish Immunol 2003; 15:169-181.
21. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-198.
22. Park Y, Chang YS, Lee SW, Cho SY, Kim YK, Min KU, et al. The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J Allergy Clin Immunol 2001; 108:570-576.